Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vandetanib in cisplatin-unfit urothelial cancer
ISRCTN68146831Phase 2Completed
- Sponsor
- Cardiff University
- Start
- Jul 2010
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of vandetanib in transitional cell carcinoma (TCC) (2 arms), sponsored by Cardiff University. Primary endpoint: Progression-free survival at 26 weeks. Started Jul 2010; status: completed.
02
Drugs
vandetanib
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on ISRCTN68146831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN68146831.